Sage Therapeutics, Inc.

BST:SG7 Stock Report

Market Cap: €365.0m

Sage Therapeutics Management

Management criteria checks 1/4

Sage Therapeutics' CEO is Barry Greene, appointed in Dec 2020, has a tenure of 4.42 years. total yearly compensation is $7.11M, comprised of 11.7% salary and 88.3% bonuses, including company stock and options. directly owns 0.16% of the company’s shares, worth €583.90K. The average tenure of the management team and the board of directors is 1.2 years and 9.8 years respectively.

Key information

Barry Greene

Chief executive officer

US$7.1m

Total compensation

CEO salary percentage11.68%
CEO tenure4.4yrs
CEO ownership0.2%
Management average tenure1.2yrs
Board average tenure9.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Barry Greene's remuneration changed compared to Sage Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$354m

Dec 31 2024US$7mUS$831k

-US$401m

Sep 30 2024n/an/a

-US$338m

Jun 30 2024n/an/a

-US$446m

Mar 31 2024n/an/a

-US$503m

Dec 31 2023US$6mUS$799k

-US$541m

Sep 30 2023n/an/a

-US$656m

Jun 30 2023n/an/a

-US$592m

Mar 31 2023n/an/a

-US$558m

Dec 31 2022US$6mUS$761k

-US$533m

Sep 30 2022n/an/a

-US$510m

Jun 30 2022n/an/a

-US$503m

Mar 31 2022n/an/a

-US$484m

Dec 31 2021US$59mUS$735k

-US$458m

Sep 30 2021n/an/a

US$642m

Jun 30 2021n/an/a

US$666m

Mar 31 2021n/an/a

US$637m

Dec 31 2020US$836kUS$53k

US$606m

Compensation vs Market: Barry's total compensation ($USD7.11M) is above average for companies of similar size in the German market ($USD963.69K).

Compensation vs Earnings: Barry's compensation has increased whilst the company is unprofitable.

CEO

Barry Greene (61 yo)

4.4yrs
Tenure
US$7,112,589
Compensation

Mr. Barry E. Greene serves as President and Chief Executive Officer at Sage Therapeutics, Inc. since December 15, 2020 and serves as Director since October 1, 2020. Mr. Greene joined the Sage Therapeutics,...

Leadership Team

NamePositionTenureCompensationOwnership
Barry Greene
President4.4yrsUS$7.11m0.16%
€ 583.9k
Christopher Benecchi
COO & Treasurerless than a yearUS$2.60m0.019%
€ 70.3k
Gregory Shiferman
Senior VPless than a yearUS$1.17mno data
Michael Quirk
Chief Scientific Officer & Interim Head of R&D1.8yrsno data0.036%
€ 129.8k
Ashley Kaplowitz
Director of Investor Relationsno datano datano data
Pamela Herbster
VP & Head of Peopleless than a yearno datano data
Helen Colquhoun
Senior Vice President of Drug Safety & Pharmacovigilanceno datano datano data
Vanessa Procter
Senior Vice President of Corporate Affairs3.5yrsno datano data
Aaron Koenig
Medical Director of Early Clinical Developmentno datano datano data
Jeff Boyle
Investor Contactno datano datano data
Helen Rubinstein
Investor Relations Officerno datano datano data
1.2yrs
Average Tenure

Experienced Management: SG7's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Barry Greene
President4.6yrsUS$7.11m0.16%
€ 583.9k
Michael Cola
Independent Director10.7yrsUS$167.22k0%
€ 0
James Frates
Independent Director11yrsUS$169.31k0.0045%
€ 16.6k
David Farb
Member of Scientific Advisory Boardno datano datano data
Geno Germano
Independent Chair of the Board8.8yrsUS$190.49k0%
€ 0
Michael Rogawski
Member of Scientific Advisory Boardno datano datano data
James Audia
Member of Scientific Advisory Boardno datano datano data
Christine Marx
Member of Scientific Advisory Boardno datano datano data
A. Morrow
Member of Scientific Advisory Boardno datano datano data
Stephen Moss
Member of Scientific Advisory Boardno datano datano data
Scott Runyon
Member of Scientific Advisory Boardno datano datano data
Donald Stein
Member of Scientific Advisory Boardno datano datano data
9.8yrs
Average Tenure
63yo
Average Age

Experienced Board: SG7's board of directors are considered experienced (9.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/11 21:34
End of Day Share Price 2025/02/11 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sage Therapeutics, Inc. is covered by 34 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Esther Lannie HongBerenberg
Gary NachmanBMO Capital Markets Equity Research